Cavrotolimod is a toll-like receptor 9 agonist that is designed to induce anticancer immune responses through proprietary spherical nucleic acid (SNA™) technology.
The sensitivity of reflectance confocal microscopy is evaluated in the context of basal cell carcinoma diagnosis.
Population data was used to assess risk for sebaceous carcinoma and overall patient survival in the transplant population.
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i.
Histology slides, clinical data used to predict immune checkpoint inhibitor response in advanced melanoma.